BioSpace News Archive

electroCore, Inc. today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of the market on Wednesday, May 8, 2024.

Hoth Therapeutics, Inc. is scheduled to attend the EF Hutton Annual Global Conference in New York, NY.

Emergent BioSolutions Inc. announced the results of a new national public opinion survey showing that more than 90 percent of Americans surveyed recognize opioid overdoses are a pressing concern for teenagers and college students, and more than 9 in 10 parents in the survey agree schools should do more to educate on the risks of opioids and how to respond to an overdose.

Affini-T Therapeutics, Inc. today announced that data from its preclinical gene edited HLA-A*11:01 KRAS G12D (AFNT-212) and HLA-A*02:01 TP53 R175H T Cell Receptor (TCR) T cell therapy products for the treatment of solid cancers will be presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting held in Baltimore, MD May 7-11.

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and...

Olympus announced the availability of the new DVM-B2 Digital Video Monitor, an all-in-one video processor and monitor for use with single-use endoscopes for both bronchoscopy and ENT including the H-SteriScope™ Single-use Flexible Bronchoscopes and the E-SteriScope™ Single-use Flexible Rhinolaryngoscopes.

ADC Therapeutics SA announced that the Company has made grants of options to purchase an aggregate of 147,600 of the Company’s common shares to four new employees on May 1, 2024.

Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024.

Catalyst Pharmaceuticals, Inc. today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst’s management team, will participate at the upcoming BofA Securities Health Care Conference.

Poolbeg Pharma announces that, further to its announcement on20 March 2024,the Company has received the fully granted patent from the US Patent Office for its Immunomodulator II patent application.